82 related articles for article (PubMed ID: 38526946)
1. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Risk Profiles for Hepatic Steatosis Differ by Race/Ethnicity: An Elastography-Based Study of US Adults.
Zhou K; Dodge JL; Yuan L; Terrault NA
Dig Dis Sci; 2022 Jul; 67(7):3340-3355. PubMed ID: 34173916
[TBL] [Abstract][Full Text] [Related]
3. Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population.
De Vincentis A; Tavaglione F; Namba S; Kanai M; Okada Y; Kamatani Y; Maurotti S; Pedone C; Antonelli Incalzi R; Valenti L; Romeo S; Vespasiani-Gentilucci U
Aliment Pharmacol Ther; 2024 Jun; 59(11):1402-1412. PubMed ID: 38497224
[TBL] [Abstract][Full Text] [Related]
4. The associations between fibrosis changes and liver-related events in patients with metabolic dysfunction-associated steatotic liver disease.
Lee HW; Kim KH; Ahn SH; Lee HC; Choi J
Liver Int; 2024 Jun; 44(6):1448-1455. PubMed ID: 38488679
[TBL] [Abstract][Full Text] [Related]
5. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
6. Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
Kobayashi T; Iwaki M; Nogami A; Kawamura N; Honda Y; Ogawa Y; Imajo K; Yoneda M; Saito S; Nakajima A
J Gastroenterol; 2024 Jan; 59(1):56-65. PubMed ID: 37845417
[TBL] [Abstract][Full Text] [Related]
7. MAFLD identifies patients with significant hepatic fibrosis better than MASLD.
Pan Z; Al-Busafi SA; Abdulla M; Fouad Y; Sebastiani G; Eslam M
Hepatol Int; 2024 Jun; 18(3):964-972. PubMed ID: 38717690
[TBL] [Abstract][Full Text] [Related]
8. The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD.
Chouik Y; Aubin A; Maynard-Muet M; Segrestin B; Milot L; Hervieu V; Zoulim F; Disse E; Levrero M; Caussy C
Obesity (Silver Spring); 2024 Jun; 32(6):1114-1124. PubMed ID: 38699960
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity.
Chan WK; Petta S; Noureddin M; Goh GBB; Wong VW
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S23-S40. PubMed ID: 38813831
[TBL] [Abstract][Full Text] [Related]
10. Adherence to a Traditional Mexican Diet Is Associated with Lower Hepatic Steatosis in US-Born Hispanics of Mexican Descent with Overweight or Obesity.
Lopez-Pentecost M; Tamez M; Mattei J; Jacobs ET; Thomson CA; Garcia DO
Nutrients; 2023 Dec; 15(23):. PubMed ID: 38068856
[TBL] [Abstract][Full Text] [Related]
11. Association between long working hours and metabolic dysfunction-associated steatotic liver disease: a nationwide population-based study in Korea.
Baek SU; Won JU; Lee YM; Yoon JH
Public Health; 2024 May; 232():188-194. PubMed ID: 38796916
[TBL] [Abstract][Full Text] [Related]
12. Body weight variability and the risk of liver-related outcomes in type 2 diabetes and steatotic liver disease: a cohort study.
Leite NC; Cardoso CRL; Villela-Nogueira CA; Salles GF
Obesity (Silver Spring); 2024 Jun; 32(6):1210-1218. PubMed ID: 38664236
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
Kalligeros M; Vassilopoulos A; Vassilopoulos S; Victor DW; Mylonakis E; Noureddin M
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1330-1332.e4. PubMed ID: 37949334
[TBL] [Abstract][Full Text] [Related]
14. Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease.
Fragkou N; Vlachaki E; Goulis I; Sinakos E
World J Hepatol; 2024 May; 16(5):671-677. PubMed ID: 38818299
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
[TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population.
Ciardullo S; Ballabeni C; Trevisan R; Perseghin G
Dig Liver Dis; 2021 Jul; 53(7):866-872. PubMed ID: 33685807
[TBL] [Abstract][Full Text] [Related]
17. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
18. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
Long MT; Zhang X; Xu H; Liu CT; Corey KE; Chung RT; Loomba R; Benjamin EJ
Hepatology; 2021 Feb; 73(2):548-559. PubMed ID: 33125745
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
Zhang X; Heredia NI; Balakrishnan M; Thrift AP
PLoS One; 2021; 16(6):e0252164. PubMed ID: 34081733
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
